Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial

被引：2

作者：

Wulfkuhle, J. D.

Yau, C.

Wolf, D. M.

Gallagher, R. I.

Deng, J.

Brown-Swigart, L.

Hirst, G.

Rugo, H.

Olopade, O. I.

Esserman, L.

Berry, D.

van't Veer, L.

Petricoin, E. F.

机构：

[1] George Mason Univ, Manassas, VA USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] QuantamLeap Healthcare Collaborat, Berkeley, CA USA

[4] Univ Chicago, Chicago, IL 60637 USA

[5] Berry Consultants LLC, Austin, TX USA

来源：

CANCER RESEARCH | 2016年 / 76卷

关键词：

D O I：

10.1158/1538-7445.SABCS15-P3-07-48

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3-07-48

引用

页数：1

共 50 条

[1] Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
Rugo, H. S.
Olopade, O.
DeMichele, A.
van't Veer, L.
Buxton, M.
Hylton, N.
Yee, D.
Chien, A. J.
Wallace, A.
Lyandres, J.
Davis, S.
Sanil, A.
Berry, D.
Esserman, L.
CANCER RESEARCH, 2013, 73
[2] Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial
Glas, A.
Peeters, J.
Yau, C.
Wolf, D. M.
Sanil, A.
Li, Y.
Severson, T.
Linn, S.
Buxton, M.
DeMichele, A.
Hylton, N.
Symmans, F.
Yee, D.
Paoloni, M.
Esserman, L.
Berry, D.
Rugo, H.
Olopade, O.
van 't Veer, L. J.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 173 - 173
[3] Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu, Minetta C.
Robinson, Patricia A.
Yau, Christina
Wallace, Anne M.
Chien, A. Jo
Stringer-Reasor, Erica
Nanda, Rita
Yee, Douglas
Albain, Kathy S.
Boughey, Judy C.
Han, Heather S.
Elias, Anthony D.
Kalinsky, Kevin
Clark, Amy S.
Kemmer, Kathleen
Isaacs, Claudine
Lang, Julie E.
Lu, Janice
Sanft, Tara
DeMichele, Angela
Hylton, Nola M.
Melisko, Michelle E.
Perlmutter, Jane
Rugo, Hope S.
Schwab, Richard
Symmans, W. Fraser
van't Veer, Laura J.
Haugen, Patricia K.
Wilson, Amy
Singhrao, Ruby
Asare, Smita
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
CANCER RESEARCH, 2020, 80 (04)
[4] MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Wolf, Denise M.
Yau, Christina
Sanil, Ashish
Chien, Jo
Wallace, Anne
DeMichele, Angela
Kaplan, Hank
Yee, Doug
Isaacs, Claudine
Albain, Kathy
Viscuzi, Rebecca
Boughey, Judy
Moulder, Stacey
Chui, Steven
Khan, Qamar
Styblo, Toncred
Edmiston, Kirsten
Northfelt, Donald
Elias, Anthony
Haley, Barbara
Tripathy, Debu
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian
Buxton, Meredith
Hylton, Nola
Paoloni, Melissa
Symmans, Fraser
Esserman, Laura
Berry, Don
Rugo, Hope
Olopade, Olufunmilayo I.
van 't Veer, Laura
CANCER RESEARCH, 2015, 75
[5] Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL
Park, John W.
Liu, Minetta C.
Yee, Douglas
DeMichele, Angela
van't Veer, Laura
Hylton, Nola
Symmans, Fraser
Buxton, Meredith B.
Chien, A. Jo
Wallace, Amy
Melisko, Michelle
Schwab, Richard
Boughey, Judy
Tripathy, Debashish
Kaplan, Hank
Nanda, Rita
Chui, Stephen
Albain, Kathy S.
Moulder, Stacy
Elias, Anthony
Lang, Julie E.
Edminston, Kirsten
Northfelt, Donald
Euhus, David
Khan, Qamar
Lyandres, Julia
Davis, Sarah E.
Yau, Christina
Sanil, Ashish
Esserman, Laura J.
Berry, Donald A.
CANCER RESEARCH, 2014, 74 (19)
[6] The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Albain, K. S.
Leyland-Jones, B.
Symmans, F.
Paoloni, M.
van't Veer, L.
DeMichele, A.
Buxton, M.
Hylton, N.
Yee, D.
Clennell, J. Lyandres
Yau, C.
Sanil, A.
Berry, D.
Esserman, L.
CANCER RESEARCH, 2016, 76
[7] Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Wolf, Denise M.
Yau, Christina
Sanil, Ashish
Daemen, Anneleen
Heiser, Laura
Gray, Joe
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian
Buxton, Meredith
DeMichele, Angela
Hylton, Nola
Symmans, Fraser
Yee, Doug
Paoloni, Melissa
Esserman, Laura
Berry, Don
Rugo, Hope
Olopade, Olufunmilayo
van't Veer, Laura
CANCER RESEARCH, 2015, 75
[8] Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
Nanda, Rita
Liu, Minetta C.
Yau, Christina
Asare, Smita
Hylton, Nola
Van't Veer, Laura
Perlmutter, Jane
Wallace, Anne M.
Chien, Amy Jo
Forero-Torres, Andres
Ellis, Erin
Han, Heather
Clark, Amy Sanders
Albain, Kathy S.
Boughey, Judy Caroline
Elias, Anthony D.
Berry, Donald A.
Yee, Douglas
DeMichele, Angela
Esserman, Laura
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial
Wolf, Denise M.
Yau, Christina
Wulfkuhle, Julia
Brown-Swigart, Lamorna
Asare, Smita M.
Hirst, Gillian L.
Sit, Laura
Perlmutter, Jane
Liu, Minetta
Park, John
DeMichele, Angela
Yee, Douglas
Berry, Don
Esserman, Laura
Petricoin, Emanuel
vant'Veer, Laura
CANCER RESEARCH, 2020, 80 (04)
[10] Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
Onishi, Natsuko
Li, Wen
Gibbs, Jessica
Wilmes, Lisa J.
Nguyen, Alex
Jones, Ella F.
Arasu, Vignesh
Kornak, John
Joe, Bonnie N.
Esserman, Laura J.
Newitt, David C.
Hylton, Nola M.
TOMOGRAPHY, 2020, 6 (02) : 77 - 85

← 1 2 3 4 5 →